BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Azercabtagene zapreleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Azercabtagene zapreleucel\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06680037-10830@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azercabtagene zapreleucel: Phase 1 readout est. (NCT06680037)
DESCRIPTION:Azercabtagene zapreleucel\, phase 1.\nStudy: A Study to Assess 
 the Safety and Clinical Activity of Azer-cel in Participants With B-cell M
 ediated Autoimmune Disorders\nEstimated primary completion: 1 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/azercabtagene-zapr
 eleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06680037
URL:https://assetmemo.bio/drug/azercabtagene-zapreleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03666000-10830@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azercabtagene zapreleucel: Phase 1 readout est. (NCT03666000)
DESCRIPTION:Azercabtagene zapreleucel\, phase 1.\nStudy: Dose-escalation an
 d Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants W
 ith Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Ac
 ute Lymphoblastic Leukemia (B-ALL)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/azercabtagene-zapr
 eleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03666000
URL:https://assetmemo.bio/drug/azercabtagene-zapreleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
